CARDIOCARE project celebrates major advances in protecting the heart health of older patients with breast cancer at risk of cardiotoxicity from cancer treatment

The EU-funded CARDIOCARE project is reaching its final stages, marking a significant milestone in the field of cardio-oncology. By integrating data from over 2,200 breast cancer patients, the initiative is pioneering a more personalized approach to protecting the heart health of women over 65 during cancer treatment.

Bridging Technology and Patient Care

The five-year project has united a diverse group of specialists—including cardiologists, oncologists, and computer scientists—from seven European countries. Their collaboration has centered on addressing the risks of cardiotoxicity, a common concern for older breast cancer patients undergoing chemotherapy.

A core achievement of the consortium is the creation of a comprehensive data resource. By combining clinical, imaging, and lifestyle data from 1,587 past patients and 642 currently enrolled participants, researchers have built a robust foundation for artificial intelligence tools designed to identify cardiac risks early.

Did You Know? Contrary to long-held assumptions regarding technology adoption in older populations, many patients over the age of 70 have actively participated in their care by utilizing wearable devices and mobile health applications.

Digital Tools and Biomarkers

The research team has successfully introduced two dedicated applications: ePsycHeart, which monitors quality of life and intrinsic capacity, and eHealtHeart, which supports psychological and behavioral interventions. These tools are currently being evaluated across six clinical centres to ensure real-world relevance.

Podcast: Cardiotoxicity in elderly breast cancer patients

Beyond digital tools, the project is making strides in identifying biological indicators of heart stress. Researchers have discovered links between specific gut microbiome profiles and heart health biomarkers, suggesting that certain bacterial compositions may leave women at a higher risk of heart damage during cancer therapy.

Expert Insight: The integration of AI-driven predictive models into clinical practise represents a shift toward proactive, rather than reactive, oncology care. By identifying potential cardiotoxicity up to a year in advance, clinicians may be better equipped to tailor treatment plans, potentially balancing the efficacy of cancer therapy with the preservation of long-term cardiovascular health.

Looking Toward the Future

As the project nears completion, the consortium is focused on consolidating its findings for publication in peer-reviewed journals. Future developments may include the widespread clinical adoption of these AI-based prognostic models, which are designed to support, rather than replace, professional clinical judgment.

If these models prove successful in broader clinical settings, they could become standard practise for managing treatment-related complications in older cancer patients. Analysts expect that the project’s legacy will be a more integrated, data-driven framework that prioritizes both cancer survival and the maintenance of cardiovascular quality of life.

Frequently Asked Questions

What is the primary goal of the CARDIOCARE project?
The project aims to provide more personalized and patient-centered care for women over 65 with breast cancer, specifically by identifying and mitigating the risk of heart damage (cardiotoxicity) caused by cancer treatments.

How are AI tools being used in this study?
AI is being utilized to analyze cardiac imaging and develop prognostic models that can predict the development of cardiotoxicity within three months or one year of starting treatment, as well as monitor quality-of-life decline.

What is the role of the microbiome in this research?
Researchers have identified specific bacteria in the gut microbiome that correlate with heart health biomarkers, suggesting that these profiles may indicate a higher risk for heart damage during chemotherapy.

How do you believe the integration of wearable technology and AI could change the way we approach long-term recovery after a cancer diagnosis?